Brasada Capital Management LP Acquires Shares of 12,500 Boston Scientific Co. (BSX)

Brasada Capital Management LP acquired a new stake in Boston Scientific Co. (NYSE:BSX) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 12,500 shares of the medical equipment provider’s stock, valued at approximately $442,000.

A number of other institutional investors and hedge funds have also modified their holdings of BSX. FMR LLC raised its position in Boston Scientific by 10.4% in the 2nd quarter. FMR LLC now owns 156,622,452 shares of the medical equipment provider’s stock valued at $5,121,554,000 after purchasing an additional 14,711,069 shares during the last quarter. Capital Research Global Investors raised its position in shares of Boston Scientific by 83.3% during the third quarter. Capital Research Global Investors now owns 19,394,528 shares of the medical equipment provider’s stock worth $746,689,000 after acquiring an additional 8,814,601 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Boston Scientific during the third quarter worth $115,618,000. BlackRock Inc. raised its position in shares of Boston Scientific by 2.7% during the third quarter. BlackRock Inc. now owns 112,313,832 shares of the medical equipment provider’s stock worth $4,324,083,000 after acquiring an additional 2,958,437 shares during the last quarter. Finally, MARSHALL WACE ASIA Ltd bought a new stake in shares of Boston Scientific during the third quarter worth $87,033,000. Hedge funds and other institutional investors own 91.60% of the company’s stock.

In other Boston Scientific news, EVP David A. Pierce sold 5,000 shares of the business’s stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $38.15, for a total value of $190,750.00. Following the completion of the transaction, the executive vice president now directly owns 29,201 shares of the company’s stock, valued at $1,114,018.15. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Maulik Nanavaty sold 3,038 shares of the business’s stock in a transaction dated Tuesday, January 15th. The shares were sold at an average price of $35.46, for a total value of $107,727.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 91,724 shares of company stock valued at $3,350,373. 0.73% of the stock is owned by insiders.

Shares of Boston Scientific stock opened at $40.04 on Wednesday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.58. Boston Scientific Co. has a 12 month low of $25.84 and a 12 month high of $40.33. The firm has a market cap of $54.63 billion, a P/E ratio of 27.24, a P/E/G ratio of 2.30 and a beta of 0.83.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 6th. The medical equipment provider reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.02. Boston Scientific had a return on equity of 26.80% and a net margin of 17.01%. The business had revenue of $2.56 billion during the quarter, compared to analysts’ expectations of $2.57 billion. During the same period in the previous year, the firm earned $0.34 earnings per share. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Boston Scientific Co. will post 1.56 earnings per share for the current fiscal year.

A number of research firms have recently weighed in on BSX. Canaccord Genuity restated a “buy” rating and set a $45.00 target price on shares of Boston Scientific in a research report on Monday. Guggenheim restated a “buy” rating and set a $48.00 target price on shares of Boston Scientific in a research report on Friday, February 8th. SunTrust Banks restated a “buy” rating and set a $47.00 target price on shares of Boston Scientific in a research report on Friday, February 8th. Needham & Company LLC restated a “buy” rating and set a $43.00 target price on shares of Boston Scientific in a research report on Wednesday, February 6th. Finally, Cowen set a $42.00 target price on Boston Scientific and gave the stock a “buy” rating in a research report on Monday, October 22nd. Three research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $40.46.

ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.com-unik.info/2019/02/13/brasada-capital-management-lp-acquires-shares-of-12500-boston-scientific-co-bsx.html.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Read More: What is a Derivative?

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit